ICLR Stock Recent News
ICLR LATEST HEADLINES
Icon PLC (ICLR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Icon PLC (ICLR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
DUBLIN--(BUSINESS WIRE)--ICON plc to Present at Upcoming Investor Conferences.
ICON's (ICLR) solid performance in the fourth quarter reflects continued market leadership across customer segments it serves.
Icon PLC (ICLR) came out with quarterly earnings of $3.46 per share, beating the Zacks Consensus Estimate of $3.44 per share. This compares to earnings of $3.13 per share a year ago.
ICON Public is a global clinical research organization that provides services for the pharmaceutical, biotechnology, and medical device industries. The clinical research organization sector is expected to have strong growth due to increased drug research and development, providing opportunities for ICON's growth. The company has been 'digesting' a huge 2021 merger that loaded it with debt and diluted outstanding shares.
DUBLIN--(BUSINESS WIRE)--ICON plc Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call.
The market's response after ICON's Q3 numbers indicates it is forecasting a period of better business for the company in 2024. ICLR's projected earnings growth out to 2025 is 9-14% on sales growth of 5-7%. Despite a strong company, current multiples are expensive, increasing starting valuations and reducing short-term return potential.
Icon PLC (ICLR) could produce exceptional returns because of its solid growth attributes.
Nvidia is leading the artificial intelligence revolution, and that's not likely to change. The world will always need new drugs, and Icon can help bring them to market.